^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

RG6129

i
Other names: RG6129, RO7444973
Associations
Trials
Company:
Roche
Drug class:
CD3 agonist, MAGE-A4 inhibitor
Related drugs:
Associations
Trials
over1year
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov)
P1, N=23, Terminated, Hoffmann-La Roche | N=260 --> 23 | Trial completion date: Feb 2024 --> Jul 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Jul 2023; The study was terminated due to program discontinuation.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02 • MAGEA4 expression
|
Actemra IV (tocilizumab) • RG6129
almost2years
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (clinicaltrials.gov)
P1, N=260, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Feb 2024 | Trial primary completion date: Oct 2026 --> Feb 2024
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02 • MAGEA4 expression
|
Actemra IV (tocilizumab) • RG6129
almost3years
Enrollment open
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02 • MAGEA4 expression
|
Actemra IV (tocilizumab) • RG6129
3years
New P1 trial
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
|
HLA-A*02 • MAGEA4 expression
|
Actemra IV (tocilizumab) • RG6129